Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel
Copyright © 2020 Elsevier Inc. All rights reserved..
The chemotherapeutic efficacy of paclitaxel against hypoxic tumors is usually unsatisfactory, which is partially due to the so-called hypoxia-induced drug resistance. The mechanism of hypoxia-induced resistance is primarily associated with hypoxia-inducible factor 1α (HIF-1α), which is an oxygen-sensitive transcriptional activator coordinating the cellular response to hypoxia. Apigenin is a natural occurring HIF-1α inhibitor that can suppress the expression of HIF-1α through multiple pathways and reverse the hypoxia-induced resistance found in cancer cells. Here we report that the use of apigenin can suppress the HIF-1α expression in hypoxic tumors through the simultaneous inhibition of the AKT/p-AKT pathway and HSP90, which is beneficial for enhancing the anticancer activity of the co-administered paclitaxel. The potential synergistic effect of apigenin and paclitaxel was further validated on HepG2 cell line and tumor-bearing mouse models.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:526 |
|---|---|
| Enthalten in: |
Biochemical and biophysical research communications - 526(2020), 2 vom: 28. Mai, Seite 321-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Ke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7V515PI7F6 |
|---|
| Anmerkungen: |
Date Completed 04.12.2020 Date Revised 14.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbrc.2020.03.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308062876 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308062876 | ||
| 003 | DE-627 | ||
| 005 | 20231225130929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbrc.2020.03.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308062876 | ||
| 035 | |a (NLM)32220496 | ||
| 035 | |a (PII)S0006-291X(20)30477-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Ke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2020 | ||
| 500 | |a Date Revised 14.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a The chemotherapeutic efficacy of paclitaxel against hypoxic tumors is usually unsatisfactory, which is partially due to the so-called hypoxia-induced drug resistance. The mechanism of hypoxia-induced resistance is primarily associated with hypoxia-inducible factor 1α (HIF-1α), which is an oxygen-sensitive transcriptional activator coordinating the cellular response to hypoxia. Apigenin is a natural occurring HIF-1α inhibitor that can suppress the expression of HIF-1α through multiple pathways and reverse the hypoxia-induced resistance found in cancer cells. Here we report that the use of apigenin can suppress the HIF-1α expression in hypoxic tumors through the simultaneous inhibition of the AKT/p-AKT pathway and HSP90, which is beneficial for enhancing the anticancer activity of the co-administered paclitaxel. The potential synergistic effect of apigenin and paclitaxel was further validated on HepG2 cell line and tumor-bearing mouse models | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Apigenin | |
| 650 | 4 | |a HIF-1α | |
| 650 | 4 | |a Hypoxia-induced drug resistance | |
| 650 | 4 | |a Paclitaxel | |
| 650 | 7 | |a Antineoplastic Agents, Phytogenic |2 NLM | |
| 650 | 7 | |a Apigenin |2 NLM | |
| 650 | 7 | |a 7V515PI7F6 |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Li, Menghuan |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Yulan |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yonglin |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Fei, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Yuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Kaiyong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical and biophysical research communications |d 1960 |g 526(2020), 2 vom: 28. Mai, Seite 321-327 |w (DE-627)NLM000000035 |x 1090-2104 |7 nnns |
| 773 | 1 | 8 | |g volume:526 |g year:2020 |g number:2 |g day:28 |g month:05 |g pages:321-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbrc.2020.03.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 526 |j 2020 |e 2 |b 28 |c 05 |h 321-327 | ||